Emergent Biosolutions Inc (EBS)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NYSE
Market Cap: $298.72M
Last updated: Nov 17, 2026 at 4:15 PM ET
Emergent Biosolutions Inc (EBS) Statistics
Emergent Biosolutions (EBS) has a market cap of $298.72M and an enterprise value of $630.72M. It kept -40.16% of revenue as net income over the last 12 months. Its net debt of $332.00M equals 111.14% of its market cap.
Total Valuation
Enterprise value is 111.14% above the market cap, as debt exceeds cash.
| Market Cap | $298.72M |
|---|---|
| Enterprise Value | $630.72M |
| Latest price (Nov 17, 2026) | $5.61 |
Key Dates
The next earnings report is expected on Feb 24, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Feb 24, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 2, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 0.4x and 0.9x. Its year-end P/S ranged from 0.1x to 3.8x from 2016 to 2025.
| Forward P/E | 19.2x |
|---|---|
| P/S Ratio | 0.4x |
| Forward P/S | 0.5x |
| P/B Ratio | 0.9x |
| P/TBV Ratio | 4.7x |
| P/FCF Ratio | 1.5x |
| P/OCF Ratio | 1.5x |
Enterprise Valuation
Counting debt and cash, the company is valued at 3.3x free cash flow.
| EV / Sales | 1.0x |
|---|---|
| EV / FCF | 3.3x |
Price Statistics
The stock is down 44.51% over 52 weeks and trades 13.56% below its 50-day average.
| Beta (1Y) | 1.11 |
|---|---|
| 52-Week Change | -44.51% |
| 1-Month Change | -11.79% |
| 3-Month Change | +14.72% |
| 6-Month Change | -30.40% |
| 5-Year Change | -85.71% |
| 10-Year Change | -74.51% |
| Total Return (1Y) | -44.51% |
| Total Return (3Y CAGR) | +39.86% |
| Total Return (5Y CAGR) | -32.31% |
| Return vs SPY (1Y) | -56.12% |
| Max Drawdown (1Y) | -67.99% |
| Max Drawdown (3Y) | -71.16% |
| Sharpe Ratio (1Y) | -0.81 |
| Correlation with SPY (1Y) | 0.21 |
| 50-Day Average | $6.49 |
| 200-Day Average | $7.68 |
| 52-Week Range | $4.36 to $14.06 |
| RSI (14 Days) | 35.5 |
| Average Volume (20 Days) | 1.05M |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 4.58x current liabilities, and total debt is 1.62x shareholder equity.
| Current Ratio | 4.58x |
|---|---|
| Quick Ratio | 2.27x |
| Debt / Equity | 1.62x |
| Debt / FCF | 2.69x |
| Interest Coverage | 2.16x |
Returns and Efficiency
Return on invested capital is -20.54% over the last 12 months, against a 5-year average of -7.77%.
| Return on Equity (ROE) | -83.24% |
|---|---|
| Return on Assets (ROA) | -26.20% |
| Return on Invested Capital (ROIC) | -20.54% |
| Return on Capital Employed (ROCE) | -19.31% |
| ROE (5Y Average) | -29.63% |
| ROA (5Y Average) | -10.14% |
| ROIC (5Y Average) | -7.77% |
| Asset Turnover | 0.53x |
| Inventory Turnover | 1.15x |
| Receivables Turnover | 4.85x |
| Cash Conversion Cycle | 338 days |
Scores
EBS has an Altman Z-Score of 0.36, in the distress zone below 1.81, and a Piotroski F-Score of 7 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 0.36 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 7 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $649.10M over the last 12 months is down 17.72% from the 12 months before.
| Revenue | $649.10M |
|---|---|
| Revenue Growth (YoY) | -17.72% |
| Gross Profit | $314.30M |
| Operating Income | -$179.80M |
| Pretax Income | -$240.00M |
| Net Income | -$260.70M |
| EBITDA | -$73.00M |
| EBIT | -$168.60M |
| Reported EPS (TTM) | -$0.04 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 31.47% of the $995.20M in total assets.
| Cash and Equivalents | $175.70M |
|---|---|
| Total Debt | $507.70M |
| Net Debt | $332.00M |
| Net Debt Per Share | $6.47 |
| Working Capital | $436.20M |
| Shareholder Equity | $313.20M |
| Book Value Per Share | $6.11 |
| Tangible Book Value | $60.70M |
| Tangible Book Per Share | $1.18 |
| Total Assets | $995.20M |
| Total Liabilities | $682.00M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $11.70M of capital spending, operating cash flow left $188.40M of free cash flow.
| Operating Cash Flow | $200.10M |
|---|---|
| Capital Expenditures | $11.70M |
| Free Cash Flow | $188.40M |
| FCF Per Share | $3.67 |
| Depreciation and Amortization | $95.60M |
| Share Repurchases | $27.20M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -27.70%.
| Gross Margin | 48.42% |
|---|---|
| Operating Margin | -27.70% |
| Pretax Margin | -36.97% |
| Net Margin | -40.16% |
| EBITDA Margin | -11.25% |
| EBIT Margin | -25.97% |
| FCF Margin | 29.02% |
| Gross Margin (5Y Average) | 58.17% |
Growth
Revenue grew 433.23% a year over 3 years.
| Revenue Growth (3Y CAGR) | +433.23% |
|---|---|
| Revenue Growth (5Y CAGR) | -13.98% |
| EPS Growth (5Y CAGR) | -28.18% |
| FCF Growth (5Y CAGR) | -16.87% |
| Book Value Per Share Growth (2Y CAGR) | -10.71% |
| Tangible Book Per Share Growth (2Y CAGR) | +1.55% |
Dividends and Yields
EBS does not pay a dividend. Its free cash flow yield is 65.46%.
| FCF Yield | 65.46% |
|---|---|
| Buyback Yield | 9.28% |
| Shareholder Yield | 9.28% |
Peer Position
Against 9 similar companies, EBS has the 8th highest P/S.
P/S RatioPeer median 1.4x
ROICPeer median -17.82%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +10.75%
| P/S Ratio | 0.4x vs 1.4x median |
|---|---|
| ROIC | -20.54% vs -17.82% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | -17.72% vs +10.75% median |
Analyst Forecast
Consensus estimates put revenue growth at -2.70% and EPS growth at -16.48% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | -2.70% |
|---|---|
| EPS Growth Forecast (2Y CAGR) | -16.48% |
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Fairly valued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About EBS
What is EBS's market cap?
Emergent Biosolutions has a market cap of $298.72M. Its enterprise value, which adds debt and subtracts cash, is $630.72M.
How many shares of EBS are outstanding?
Emergent Biosolutions has 51.30M shares outstanding. The count is down 3.57% from a year earlier.
Does EBS pay a dividend?
No. Emergent Biosolutions does not pay a dividend.
How much debt does EBS have?
Emergent Biosolutions has $507.70M of total debt and $175.70M of cash and equivalents, a net debt position of $332.00M.
EBS pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors, Government Contracts